Xeljanz, Xeljanz XR tofacitinib : Drug safety communication — Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine | In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management |
---|---|
The facts about inflammatory bowel diseases | Surveillance and management of dysplasia in patients with inflammatory bowel disease |
Epidemiology, pathogenesis, and diagnosis of inflammatory bowel diseases.
8Feldman M, et al, eds | |
---|---|